JP2005247724A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005247724A5 JP2005247724A5 JP2004058125A JP2004058125A JP2005247724A5 JP 2005247724 A5 JP2005247724 A5 JP 2005247724A5 JP 2004058125 A JP2004058125 A JP 2004058125A JP 2004058125 A JP2004058125 A JP 2004058125A JP 2005247724 A5 JP2005247724 A5 JP 2005247724A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- butenyloxy
- isobutyl
- methyl
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 93
- 210000004027 cells Anatomy 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 31
- 108060003412 GRP Proteins 0.000 claims description 20
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 20
- 241001486992 Taiwanofungus camphoratus Species 0.000 claims description 20
- OJSZXJGYUVZRNU-UHFFFAOYSA-N 1-hydroxy-3-[4-(3-methylbut-2-enoxy)phenyl]-4-(2-methylpropyl)pyrrole-2,5-dione Chemical compound O=C1N(O)C(=O)C(CC(C)C)=C1C1=CC=C(OCC=C(C)C)C=C1 OJSZXJGYUVZRNU-UHFFFAOYSA-N 0.000 claims description 14
- AILGRWSIRAPLCJ-UHFFFAOYSA-N 3-[4-(3-methylbut-2-enoxy)phenyl]-4-(2-methylpropyl)pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(CC(C)C)=C1C1=CC=C(OCC=C(C)C)C=C1 AILGRWSIRAPLCJ-UHFFFAOYSA-N 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 230000001713 cholinergic Effects 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 230000035488 systolic blood pressure Effects 0.000 claims description 10
- ZXIUCXGVUOQMSH-UHFFFAOYSA-N 3-[4-(3-methylbut-2-enoxy)phenyl]-4-(2-methylpropyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(CC(C)C)=C1C1=CC=C(OCC=C(C)C)C=C1 ZXIUCXGVUOQMSH-UHFFFAOYSA-N 0.000 claims description 9
- 230000000259 anti-tumor Effects 0.000 claims description 9
- 230000003110 anti-inflammatory Effects 0.000 claims description 7
- 210000004185 Liver Anatomy 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 210000004369 Blood Anatomy 0.000 claims description 3
- 210000000988 Bone and Bones Anatomy 0.000 claims description 3
- 210000000481 Breast Anatomy 0.000 claims description 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 3
- 210000000936 Intestines Anatomy 0.000 claims description 3
- 210000002751 Lymph Anatomy 0.000 claims description 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 230000002443 hepatoprotective Effects 0.000 claims description 3
- 210000001519 tissues Anatomy 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 210000004072 Lung Anatomy 0.000 claims 1
- 239000003125 aqueous solvent Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 22
- 241000700159 Rattus Species 0.000 description 22
- 108010082126 Alanine Transaminase Proteins 0.000 description 17
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 17
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 17
- 102100010966 GPT Human genes 0.000 description 17
- 239000000469 ethanolic extract Substances 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 12
- -1 CH 3 OH Chemical class 0.000 description 10
- 210000002966 Serum Anatomy 0.000 description 9
- 239000002609 media Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- LKYXEULZVGJVTG-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH] LKYXEULZVGJVTG-UHFFFAOYSA-N 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000006011 modification reaction Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000004083 survival Effects 0.000 description 7
- 229940107161 Cholesterol Drugs 0.000 description 6
- VXOZCESVZIRHCJ-KGHQQZOUSA-N Ergosterol peroxide Chemical compound O1O[C@@]2(C=C3)[C@@H]4CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]4(C)CC[C@@H]2[C@]2(C)[C@@]13C[C@@H](O)CC2 VXOZCESVZIRHCJ-KGHQQZOUSA-N 0.000 description 6
- MSWZFWKMSRAUBD-GASJEMHNSA-N Galactosamine Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 6
- 210000003141 Lower Extremity Anatomy 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 229940113118 Carrageenan Drugs 0.000 description 5
- 206010067125 Liver injury Diseases 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- 239000000679 carrageenan Substances 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 239000002026 chloroform extract Substances 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 231100000753 hepatic injury Toxicity 0.000 description 5
- 238000002329 infrared spectrum Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 5
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 150000003443 succinic acid derivatives Chemical class 0.000 description 5
- 210000004881 tumor cells Anatomy 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 4
- 206010025650 Malignant melanoma Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000001555 benzenes Chemical group 0.000 description 4
- 230000001472 cytotoxic Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000002093 peripheral Effects 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 125000006414 CCl Chemical group ClC* 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 201000010897 colon adenocarcinoma Diseases 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002538 fungal Effects 0.000 description 3
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 3
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 150000002688 maleic acid derivatives Chemical class 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- GJSURZIOUXUGAL-UHFFFAOYSA-N 2-((2,6-Dichlorophenyl)imino)imidazolidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229960004857 Mitomycin Drugs 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 241000201593 Nihon Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute Effects 0.000 description 2
- 230000001464 adherent Effects 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 201000008286 diarrhea Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000001631 hypertensive Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- XJENLUNLXRJLEZ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=C(C)C(N(CC)CC)=CC2=[O+]C=2C=C(N(CC)CC)C(C)=CC=2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O XJENLUNLXRJLEZ-UHFFFAOYSA-M 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000003442 weekly Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BUXKULRFRATXSI-UHFFFAOYSA-N 1-hydroxypyrrole-2,5-dione Chemical compound ON1C(=O)C=CC1=O BUXKULRFRATXSI-UHFFFAOYSA-N 0.000 description 1
- AZRRZGIBBLWSSQ-UHFFFAOYSA-N 4-ethyl-7-phenyl-3,5-diazabicyclo[2.2.2]octane-2,6-dione Chemical compound N1C(=O)C2C(=O)NC1(CC)CC2C1=CC=CC=C1 AZRRZGIBBLWSSQ-UHFFFAOYSA-N 0.000 description 1
- 235000001274 Anacardium occidentale Nutrition 0.000 description 1
- 240000001407 Anacardium occidentale Species 0.000 description 1
- 241000123370 Antrodia Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- OAVCWZUKQIEFGG-UHFFFAOYSA-O CC1=NN=N[NH+]1C1=NC=CS1 Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N Cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 241000386927 Cinnamomum micranthum f. kanehirae Species 0.000 description 1
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 235000004035 Cryptotaenia japonica Nutrition 0.000 description 1
- 240000008956 Cryptotaenia japonica Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N Dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 206010013663 Drug dependence Diseases 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 208000010235 Food Addiction Diseases 0.000 description 1
- 206010017758 Gastric cancer Diseases 0.000 description 1
- 238000008467 HDL Assay Methods 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N Maleic anhydride Chemical group O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 229940041334 Meclofenamate Sodium Drugs 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 210000004251 Milk, Human Anatomy 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N Silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 210000002356 Skeleton Anatomy 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N Succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000001476 alcoholic Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical group 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000003556 assay method Methods 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- YIYSEJAAJSSNNS-UHFFFAOYSA-N but-1-en-1-one Chemical group [CH2]CC=C=O YIYSEJAAJSSNNS-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 235000020226 cashew Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001055 chewing Effects 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 210000002257 embryonic structures Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000001077 hypotensive Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000004215 spores Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW93105094A TWI318877B (en) | 2004-03-02 | 2004-02-27 | Novel mixture and compounds from mycelia of antrodia camphorata having hepatoprotection,anti-inflammatory and anti-tumor activities |
JP2004058125A JP5403844B2 (ja) | 2004-03-02 | 2004-03-02 | AntrodiaCamphorataの菌糸体から得た新規な混合物及び化合物、並びにその使用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004058125A JP5403844B2 (ja) | 2004-03-02 | 2004-03-02 | AntrodiaCamphorataの菌糸体から得た新規な混合物及び化合物、並びにその使用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013189211A Division JP2013241477A (ja) | 2013-09-12 | 2013-09-12 | AntrodiaCamphorataの菌糸体から得た新規な混合物及び化合物、並びにその使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005247724A JP2005247724A (ja) | 2005-09-15 |
JP2005247724A5 true JP2005247724A5 (zh) | 2006-03-16 |
JP5403844B2 JP5403844B2 (ja) | 2014-01-29 |
Family
ID=35028563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004058125A Expired - Fee Related JP5403844B2 (ja) | 2004-03-02 | 2004-03-02 | AntrodiaCamphorataの菌糸体から得た新規な混合物及び化合物、並びにその使用 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5403844B2 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200829234A (en) * | 2007-01-08 | 2008-07-16 | Golden Biotechnology Corp | Antrodia camphorata isophorone extract |
TWI394572B (zh) * | 2007-06-12 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum aurantii Cyclohexenone Compounds in the Preparation of Drugs for the Treatment of Autoimmune Diseases |
TWI394574B (zh) * | 2007-06-14 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Mitigating Physiological Fatigue |
TWI394573B (zh) * | 2007-06-14 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Liver Protection |
TWI394575B (zh) * | 2007-07-09 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for the Suppression of Hepatitis B Virus |
JP5106935B2 (ja) * | 2007-07-17 | 2012-12-26 | 國鼎生物科技股▲ふん▼有限公司 | 生理的疲労の緩和に用いるベニクスノキタケのシクロヘキサンケトン化合物 |
CN101910125B (zh) * | 2008-01-28 | 2013-07-24 | 善笙生物科技股份有限公司 | 从牛樟芝菌丝体萃取的化合物与其用途 |
CN102643220B (zh) * | 2008-01-28 | 2014-08-13 | 善笙生物科技股份有限公司 | 从牛樟芝菌丝体萃取的化合物与其用途 |
EP2329816B1 (en) * | 2009-11-26 | 2016-04-13 | National Taiwan University | An anti-cancer active substance from antrodia camphorata, method for preparing the same and use thereof |
JP2013241477A (ja) * | 2013-09-12 | 2013-12-05 | Simpson Biotech Co Ltd | AntrodiaCamphorataの菌糸体から得た新規な混合物及び化合物、並びにその使用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52156924A (en) * | 1976-06-22 | 1977-12-27 | Ihara Chem Ind Co Ltd | Repellent for aquatic life |
TWI226370B (en) * | 2000-02-17 | 2005-01-11 | Food Industry Res & Dev Inst | Isolate of Antrodia camphorata, process for producing a culture of the same and product obtained thereby |
CN1192098C (zh) * | 2000-11-13 | 2005-03-09 | 葡萄王企业股份有限公司 | 樟芝菌丝体生物活性物质其制备法及含其组成物 |
CN1386545A (zh) * | 2001-05-18 | 2002-12-25 | 葡萄王企业股份有限公司 | 樟芝保肝制剂 |
TWI241344B (en) * | 2002-03-29 | 2005-10-11 | Food Industry Res & Dev Inst | Processes for producing an antrodia camphorata culture having pharmacological activity, processes for obtaining a pharmacologically active composition from a culture of A camphorata, products produced thereby and pharmaceutical compositions of cancer... |
-
2004
- 2004-03-02 JP JP2004058125A patent/JP5403844B2/ja not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060099222A1 (en) | Novel mixture and compounds from mycelia of antrodia camphorata and use thereof | |
EP1634877B1 (en) | Mixture and compounds from mycelia of antrodia camphorata and use thereof | |
JP5667561B2 (ja) | 4’−デメチルノビレチン又は4’−デメチルタンゲレチンを有効成分として含有する神経突起伸長剤、記憶改善剤、抗アルツハイマー剤、並びに、その製造方法 | |
JP5403844B2 (ja) | AntrodiaCamphorataの菌糸体から得た新規な混合物及び化合物、並びにその使用 | |
JP2005247724A5 (zh) | ||
US20060121132A1 (en) | TNF-alpha production inhibitor comprising kavalactone as an active ingredient | |
TWI580689B (zh) | 甾醇類衍生物及其製備方法與應用 | |
CN100386316C (zh) | 来自牛樟芝菌丝体的化合物和混合物或组合物及其用途 | |
JP2013241477A (ja) | AntrodiaCamphorataの菌糸体から得た新規な混合物及び化合物、並びにその使用 | |
KR100923124B1 (ko) | 안트로디아 캄포라타 균사체 유래의 신규한 혼합물 및화합물, 및 그의 용도 | |
CN110551166B (zh) | 一种胆酸衍生物及其制备方法和应用 | |
JP6686032B2 (ja) | 化合物、その分離方法、合成方法及び使用 | |
US20100324309A1 (en) | Novel Mixture and Compounds from Mycelia of Antrodia Camphorata and Use Thereof | |
CN1688566A (zh) | 治疗药 | |
US8648113B2 (en) | Mixture and compounds from mycelia of Antrodia camphorata and use thereof | |
KR20050091464A (ko) | 안트로디아 캄포라타 균사체 유래의 신규한 혼합물 및화합물, 및 그의 용도 | |
TW201018462A (en) | Novel mixture and compounds from mycelia of antrodia camphorata having hepatoprotection, anti-inflammatory and anti-tumor activities | |
KR100831645B1 (ko) | 항고지혈, 항산화 및 항바이러스 활성을 갖는 참취 추출물및 그로부터 분리된 화합물 | |
Huang et al. | Mesonosides AH, primeverose derivatives from Mesona procumbens suppress adipogenesis by downregulating PPARγ and C/EBPα in 3T3-L1 cells | |
KR100659771B1 (ko) | 한국산 겨우살이 유기추출물로부터 항암 화합물 베루틴과베투린 산의 정제 및 이 추출물의 제조방법 | |
CN110857285A (zh) | 取代吡唑类化合物、其制备方法、药物组合物及用途 | |
KR0184756B1 (ko) | 후박잎으로부터 아실-코에이 : 콜레스테롤 아실트랜스퍼라제 활성 저해제의 제조방법 | |
KR101594425B1 (ko) | 백선피 추출물과 이로부터 분리된 신규 글래브레탈-타입 트리테르페노이드 및 이의 용도 | |
KR100882194B1 (ko) | 항고지혈, 항산화 및 항바이러스 활성을 갖는 참취추출물로부터 분리된 화합물 | |
KR20100084038A (ko) | 물오리나무 줄기 추출물 또는 이로부터 분리된 화합물을 함유하는 간독성 질환 예방 및 치료용 조성물 |